anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Abstract. The invention provides humanized and chimeric anti-CD20 antibodies for treatment of B-Cell associated diseases such as CD20 positive malignancies and autoimmune diseases, in particular dosage regimen. The present invention is directed to CD-20 antibodies with Fc region substitutions S298A or E333A or K334A or K326A or K326W or K322A, wherein these substitutions improve ADCC or CDC activity of the antibody. Certain aspects of the invention are directed to the use of the CD-20 antibody Rituximab@ (Rituxan@) in the treatment of diseases such as rheumatoid arthritis. The present antibodies are used in treating CD 20 positive cancers such as non-Hodgkin's lymphoma, treating autoimmune disease and inducing apoptosis in B-Cells. The invention is also directed to combination therapies with further chemotherapeutic agents such as doxorubicin, cyclophosphamide, prednisolone or CHOP, with further anti-rheumatic agents or with further immunosuppressive agents such as methotrexate. The invention also encompasses methods of producing CD-20 antibodies using vectors and host cells comprising nucleotide sequences encoding the CD-20 antibodies.
This study is a prospective, randomized controlled trial assessing pain control in ankle fractures repaired with open reduction and internal fixation. Patients are consented and enrolled pre-operatively, and randomized to either control or liposomal bupivacaine with bupivacaine administered intra-operatively. Patients are to remain blinded to the treatment arm. The surgeon is non-blinded and administers the bupivacaine solution locally, intra-operatively.

Patients pain scores and pain medication usage is documented. A trained research coordinator contacts each patient at 24, 48, and 72 hours post-operatively to assess pain levels on a visual analog scale (VAS) and pain medications taken. Patients return for followup at standard intervals of 2 weeks, 6 weeks, 3 months, 6 months, and 1 year post-operatively to assess healing and functional outcomes. Patients are queried as to satisfaction with pain control at 2 weeks post-operatively. The study will compare outcomes including pain levels, pain medications taken, operating room (OR) and post-anesthesia care unit (PACU) times, length of stay (LOS), satisfaction with pain control, clinical outcomes, and complication rates.
PURPOSE: Amblyopia damages visual sensory and ocular motor functions. One manifestation of the damage is abnormal fixational eye movements. Tiny fixation movements are normal; however, when these exceed a normal range, the behavior is labeled "fixation instability" (FI). Here we compare FI between normal and amblyopic subjects, and evaluate the relationship between FI and severity of amblyopia, strabismus angle, nystagmus, stereopsis, vergence, and subject age.
METHODS: Fixation eye movements were recorded using infrared video-oculography from 47 controls (15.3 ± 12.2 years of age) and 104 amblyopic subjects (13.3 ± 11.2 years of age) during binocular and monocular viewing. FI and vergence instability were quantified as the bivariate contour ellipse area (BCEA). We also calculated the ratio of FI between the 2 eyes: right eye/left eye for controls, amblyopic eye/fellow eye for amblyopes. Multiple regression analysis evaluated how FI related to a range of visuo-motor measures.
RESULTS: During binocular viewing, the FI of fellow and amblyopic eye, vergence instability, and inter-ocular FI ratios were least in anisometropic and most in mixed amblyopia (P < .05). Each correlated positively with the strabismus angle (P < .01). During monocular viewing, subjects with deeper amblyopia (P < .01) and larger strabismus angles (P < .05) had higher inter-ocular FI ratios. In all, 27% of anisometropic and >65% of strabismic/mixed amblyopes had nystagmus. Younger age and nystagmus increased FI and vergence instability (P < .05) but did not affect the inter-ocular FI ratios (P > .05).
CONCLUSIONS: Quantitative recording of perturbed eye movements in children reveal a major functional deficit linked to amblyopia. Imprecise fixation, measured as inter-ocular FI ratios, may be used as a robust marker for amblyopia and strabismus severity. NOTE: Publication of this article is sponsored by the American Ophthalmological Society.
A process for preparing a cast metal surface such that it is usable for bonding to a tooth structure. A water soluble adhesive medium is placed on a stone cast of a tooth or teeth. A mixture of soluble and non-soluble particles are then placed onto the adhesive. The soluble particles partially dissolve into the adhesive medium while the non-soluble particles adhere to the adhesive. Wax or resin is flowed over the resultant surface to imbed the particles therein. The desired tooth form is then completed after which the adhesive is dissolved away to release the pattern from the cast. The remaining soluble particles are then washed away leaving voids in the surface of the pattern. These voids are then duplicated using standard lost wax casting procedures to reproduce the surface in metal. The surface, which has a multiplicity of voids, roughnesses, and undercuts, is then filled with a bonding medium to attach the rigid cast metal appliance to a tooth surface.
The training was designed to perform static work of the lower limbs. Patients worked in a squatting position, with 30º of hip flexion and 55º of knee flexion, holding onto the bars of the WBV platform.
Nodular heterotopia (NH)-related drug-resistant epilepsy is challenging due to the deep location of the NH and the complexity of the underlying epileptogenic network. Using ictal stereo-electroencephalography (SEEG) and functional connectivity (FC) analyses in 14 patients with NH-related drug-resistant epilepsy, we aimed to determine the leading structure during seizures. For this purpose, we compared node IN and OUT strength between bipolar channels inside the heterotopia and inside gray matter, at the group level and at the individual level. At seizure onset, the channels within NH belonging to the epileptogenic and/or propagation network showed higher node OUT-strength than the channels within the gray matter (p = .03), with higher node OUT-strength than node IN-strength (p = .03). These results are in favor of a "leading" role of NH during seizure onset when involved in the epileptogenic- or propagation-zone network (50% of patients). However, when looking at the individual level, no significant difference between NH and gray matter was found, except for one patient (in two of three seizures). This result confirms the heterogeneity and the complexity of the epileptogenic network organization in NH and the need for SEEG exploration to characterize more precisely patient-specific epileptogenic network organization.
Learned how to self-monitor their sedentary behavior and active breaks. They also learned how to create prompts/cues (e.g., sticky note reminder), problem solve to overcome barriers, action plan (i.e., specifying when, where, and how to do the behavior), and set goals in order to be less sedentary according to SMART (i.e., specific, measurable, attainable, relevant, time-oriented) principles. Received intervention following measurements at baseline, week 4, and week 8.
<P>PROBLEM TO BE SOLVED: To provide a composition having the excellent adiponectin-production induction action.  <P>SOLUTION: The composition is provided which contains the chalcon and isoflavone of Angelica keiskei. This composition takes an effect of the excellent adiponectin-production induction action, consequently the composition is useful in the fields of foods and medicines, especially useful for the prophylaxis, improvement and/or medical treatment of fatness and fatness-resultant lifestyle diseases such as circulatory diseases (arteriosclerosis, hyperlipemia, etc.) and diabetes, etc. Moreover, there is provided a method for producing such an extract derived from Angelica keiskei as contains the chalcon of Angelica keiskei with a high concentration.  <P>COPYRIGHT: (C)2011,JPO&INPIT
In patients randomized to this Arm, after induction of general anesthesia and single lung ventilation the first thoracoscopic surgical access is performed. A cryoanesthesia device with a dedicated atraumatic angled-tip cryoprobe is inserted through the thoracoscopic access and the active tip of the probe is positioned in contact with the intercostal nerves from T3 to T8.
PROBLEM TO BE SOLVED: To effectively raise and nourish hair, prevent dandruff and itch, implement skin care and treat a skin lesion respectively regarding the scalp by applying a skin treatment material to the skin for providing electrical conductivity, and sending very weak current to the skin for electrically causing reducing action and removing active oxygen as well as lipid peroxide, or preventing the generation thereof. SOLUTION: Electric current is made to flow to a skin coated with a skin treatment agent using a skin treatment appliance, and electric reducing action is thereby caused to remove active oxygen and lipid peroxide or prevent the appearance thereof. Cystine, ions or the like is used as the skin treatment agent. Furthermore, an appliance body 1 is brush type made of an insulator and has a power supply 3 within a handle 2. A negative electrode rod 4 made of a carbon rod is connected to the negative electrode side of the power supply 3, while a positive electrode 5 of a carbon rod to the positive electrode side. In addition, many electrodes 4 and 5 are implanted like a brush on a base part 8. Also, a carbon rod breakage protection rod is used to prevent an external impact to the side of the carbon rod.  In this case, when the negative electrode rod 4 is made longer than the positive electrode rod 5, only the negative electrode rod 4 comes in contact with the skin and more effective treatment can be implemented.
BACKGROUND: Growing evidence suggests that sensory impairment, particularly in the form of visual impairment, may contribute to the development of dementia. However, it remains unclear whether experiencing concurrent visual impairment in combination with other types of multisensory impairments may further increase this risk.
METHODS: The study used data from the UK Biobank cohort study, which recruited 500,000 adults. With meticulous screening procedures in place, individuals with visual impairment, hearing impairment, and oral health issues were identified for further follow-up evaluations. A multivariable regression analysis was conducted to investigate the relationship between multisensory impairments concurrent with visual impairment and cognitive function. Cox proportional hazard models were used to estimate hazard ratios and 95% confidence intervals to evaluate the association between multisensory impairments concurrent with visual impairment and dementia risk.
RESULTS: Subjects experiencing multisensory impairments concurrent with visual impairment demonstrated a negative association with cognitive function. Notably, individuals who have both vision and hearing impairments had a significantly higher risk of developing dementia (HR 1.28, 95% CI [1.01-1.63]). Additionally, individuals who experience vision impairment and oral health issues simultaneously were also at higher risk for dementia (HR 1.61, 95% CI [1.32-1.97]). Furthermore, the risk of dementia among individuals with vision impairment, hearing impairment, and oral health issues further escalated to an even higher level (HR 1.63, 95% CI [1.19-2.24]).
CONCLUSIONS: The correlation between the presence of multisensory impairments concurrent with visual impairment and cognitive decline is highly significant. Those with multisensory impairments concurrent with visual impairment are at a significantly increased risk of developing dementia.
An estimated 19,500 cardiac events could be prevented each year in Canada by use of statin therapy as recommended in the Canadian Cardiovascular Society's Lipid Guidelines. Despite substantial evidence supporting statin use, several studies suggest dyslipidemia management in Canada remains suboptimal. In Ontario, prior work using the 2008 Cardiovascular Health in Ambulatory Care Research Team (CANHEART) 'big data' registry of almost the entire Ontario population of 9.8 million adults created through linkage of 17+ population health databases at ICES, has documented an approximate 2-fold variation across the province in cardiovascular events that is associated with performance of key cardiovascular preventive measures, particularly lipid screening and statin prescribing. This work noted that the variation did not have a clear association with traditional clinical risk factors or socioeconomic conditions. This observation suggests that heterogeneity in this care process may be modifiable with an intervention geared to improving adherence to national guidelines.

In this pragmatic, cluster randomized registry trial, 'big data' is used to test the 'real world' effectiveness of a tailored, multicomponent intervention strategy aimed at improving lipid management (screening, risk assessment, statin initiation, statin adherence) amongst a primary prevention cohort of 40 to 75 year olds individuals living in 14 (of 28) communities in Ontario with higher than average rates of cardiovascular events. A multicomponent intervention strategy will include a 'toolbox' of lipid management resources for both patient and physicians in the intervention (high-risk) communities of the province. The intervention strategy will include tools to enable patients and physicians to make informed and shared decisions about statin therapy and will be implemented in the intervention communities using targeted local and social media strategies. Patient characteristics for those aged 40 to 75 and clinical outcomes in this study will be measured without primary data collection using the 2016 CANHEART 'big data' registry, with the exception of stain use and adherence data available only in adults 66 to 75 years old.
Neonatal encephalopathy (NE) due to hypoxia-ischemia is a major public health concern as it occurs in 6/1000 live term births and has devastating consequences. Many affected neonates suffer lifelong motor disabilities and epilepsy, but increasingly the high prevalence of cognitive and behavioral disabilities is becoming appreciated. In hypoxia-ischemia there is a decrease in blood and oxygen delivery, followed by reperfusion with transient energy recovery. What follows is a "window of opportunity" where excitotoxicity and associated increased cerebral metabolism eventually lead to secondary energy failure and irreversible cell death. In this window, therapeutic hypothermia (TH) is currently the only treatment available with proven efficacy. TH acts primarily by decreasing cerebral metabolism, thus preserving energy stores.

Although the current gold standard for brain injury detection is magnetic resonance imaging (MRI), MRI is impractical as a screening tool and cannot provide bedside monitoring to optimize individual responses to therapies. Commercially available continuous wave (CW) near infrared spectroscopy (NIRS) systems provide bedside measures of cerebral oxygen saturation (SO2) but SO2 alone cannot assess oxygen metabolism, as oxygen delivery is not taken into account. What is needed is a bedside tool that can monitor cerebral metabolism to detect elevations in metabolism that suggest evolving hypoxic-ischemic injury, and decreases in metabolism that suggest response to therapy. Cerebral oxygen consumption (CMRO2) is a direct measure of cerebral metabolism and therefore the investigators propose to measure an index of CMRO2 at the bedside using the innovative combination of Frequency Domain Near-Infrared Spectroscopy (FDNIRS) and Diffuse Correlation Spectroscopy (DCS). The initial studies from the investigators show that CMRO2 is elevated in neonates with MRI evidence of perinatal brain injury, and confirm that neonates on TH have significantly lower CMRO2 than normal controls. Following these exciting results, they now propose a feasibility study to determine if FDNIRS-DCS can screen for involvement, assess response to treatment, and predict outcomes in one of the largest neonatal populations requiring early screening and immediate intervention: neonatal encephalopathy. To assess early outcomes, the research team proposes an innovative combination of advanced neurobehavioral testing, regional FDNIRS-DCS measures and quantitative MRI analysis using MRIs obtained without sedation. If the hypotheses prove true, it will help in determining if bedside indices of CMRO2 provided by FDNIRS-DCS can optimize TH for individual neonates, thereby improving neurodevelopmental outcomes. Success at this stage will also allow exploration of the potential for FDNIRS-DCS to determine the additional benefits of emerging new treatments for NE and to screen for other treatable neonatal disorders.
The invention discloses a method for extracting flavonoids from camphor tree leaves. The method provided by the invention comprises the steps that: (1) camphor tree leaves are dried and are soaked in ethanol; alcohol-soluble substances are extracted by heating and refluxing; heating is stopped, and filtering is carried out, such that camphor tree leaf tincture is obtained; (2) the camphor tree leaf tincture is heated and distilled, such that ethanol is recovered, and a camphor tree leaf extract is obtained; (3) ligroin is added to the camphor tree leaf extract, and stirring is carried out; the mixture is filtered, such that a filtrate and crude flavonoids are obtained; and (4) the crude flavonoids are dried, such that a finished product is obtained. According to the invention, flavonoids in dried camphor tree leaves are extracted by using industrial ethanol. The technological process is simple, and the requirements on equipment are low, such that the method is suitable for industrialized productions. With the method provided by the invention, the efficiency of flavonoid extraction is high. The source of camphor tree leaves adopted by the invention is wide, such that the resource is fully utilized, and the production cost of the flavonoids is reduced.
Patients receive anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
Ten subjects will be randomly assigned in a ratio of 4:1 to receive 30mg of PA1010 tablets or 30mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
Combined anodal tDCS and cognitive training. Anodal tDCS will be delivered while the participant is completing the cognitive training task (Iowa Gambling Task). Anodal tDCS will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively. The duration of each tDCS session will be 20 minutes.
The oil (coconut oil) was applied by the trained nurse to the entire body surface of infant except the face two times a day started as early as possible Four ml of coconut oil was applied using both hands of the caregiver in four strokes starting from the level of clavicles over the chest and abdomen till the groin, from the front of thighs, knee, leg and upto the sole, from above the shoulders over the arm and forearm till the palm continuing medially over the forearm and arm till the axilla and the final stroke was used for the back reaching over the back of the thighs till the heel. Just prior to the first application, and thereafter prior to the subsequent applications the TEWL was recorded using the portable closed chamber evaporimeter. The oil application was continued twice daily (every 12 hrs at the same time as the hour of birth e.g. 11 am and 11pm) till the completion of the seventh day (168 hrs of life)..
Means to decrease the effects of polymerization shrinkage, increase stiffness, decrease the coefficient of thermal expansion to a greater extent than previously possible, and improve the durability of composite restorations by use of improved microcrystalline glass inserts. Shaped pieces of assorted sizes within the range of one-half to 10 millimeters are heat treated to produce microcrystallinity in which the crystalline phases, such as for example stuffed beta quartz, beta-eucryptite, beta-spodumene solid solutions, and keatite and/or other phases, give the microcrystalline glass pieces exceptionally low coefficients of thermal expansion and other desirable properties. Compositions and heat treatment conditions are given to provide the insert pieces with the desired translucencies/opacities, colors, and shades, to match a range of those properties found in teeth. Treatment of the inserts with an organofunctional silane with or without an additional resin coating provides for chemical bonding with composite resins. Cavities in teeth are partially filled with unhardened composite material, and microcrystalline glass inserts of appropriate size, shape and appearance are pressed into the cavity so that the insert constitutes as much as possible of the finished restoration. The composite containing the insert is polymerized either by light, chemical, or combined cure mechanisms, and contoured and polished.
Huntingtin (HTT) protein is expressed in most cell lineages, and the toxicity of mutant HTT in multiple organs may contribute to the neurological and psychiatric symptoms observed in Huntington's disease (HD). The proteostasis and neurotoxicity of mutant HTT are influenced by the intracellular milieu and responses to environmental signals. Recent research has highlighted a prominent role of gut microbiota in brain and immune system development, aging, and the progression of neurological disorders. Several studies suggest that mutant HTT might disrupt the homeostasis of gut microbiota (known as dysbiosis) and impact the pathogenesis of HD. Dysbiosis has been observed in HD patients, and in animal models of the disease it coincides with mutant HTT aggregation, abnormal behaviors, and reduced lifespan. This review article aims to highlight the potential toxicity of mutant HTT in organs and pathways within the microbiota-gut-immune-central nervous system (CNS) axis. Understanding the functions of Wild-Type (WT) HTT and the toxicity of mutant HTT in these organs and the associated networks may elucidate novel pathogenic pathways, identify biomarkers and peripheral therapeutic targets for HD.